DNTH Dianthus Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DNTH

Price (delayed)

$93.44

Market cap

$5.23B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.24

Enterprise value

$5.12B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 28
Highlights
DNTH's debt is down by 6% since the previous quarter and by 3.2% year-on-year
Dianthus Therapeutics's quick ratio has surged by 101% YoY but it has decreased by 11% QoQ
The revenue has plunged by 61% YoY but it has grown by 43% from the previous quarter
Dianthus Therapeutics's net income has shrunk by 68% YoY and by 11% QoQ
The EPS fell by 30% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.magentatx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of DNTH

DNTH stock price

How has the Dianthus Therapeutics stock price performed over time
Intraday
-4.99%
1 week
-8.83%
1 month
-15.9%
1 year
146.74%
YTD
126.74%
QTD
-4.14%

Financial performance

How have Dianthus Therapeutics's revenue and profit performed over time
Revenue
$1.9M
Gross profit
$1.9M
Operating income
-$217.84M
Net income
-$192.25M
Gross margin
100%
Net margin
-10,097%
The operating income has plunged by 68% YoY and by 14% from the previous quarter
Dianthus Therapeutics's net income has shrunk by 68% YoY and by 11% QoQ
The revenue has plunged by 61% YoY but it has grown by 43% from the previous quarter
The gross profit has dropped by 61% year-on-year but it is up by 43% since the previous quarter

Price vs fundamentals

How does DNTH's price correlate with its fundamentals

Growth

What is Dianthus Therapeutics's growth rate over time

Valuation

What is Dianthus Therapeutics stock price valuation
DNTH P/E details
P/E
N/A
P/B
4.36
P/S
2,749.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,687.63
The EPS fell by 30% YoY
The stock's price to book (P/B) is 155% more than its 5-year quarterly average of 1.8 and 35% more than its last 4 quarters average of 3.4
DNTH's equity is down by 2.4% QoQ
DNTH's P/S is 62% above its last 4 quarters average of 1787.6
The revenue has plunged by 61% YoY but it has grown by 43% from the previous quarter

Efficiency

How efficient is Dianthus Therapeutics business performance
The ROE has increased by 35% YoY and by 18% QoQ
DNTH's return on assets is up by 34% year-on-year and by 17% since the previous quarter
The ROS rose by 22% QoQ
DNTH's return on invested capital is up by 22% since the previous quarter and by 19% year-on-year

Dividends

What is DNTH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DNTH.

Financial health

How did Dianthus Therapeutics financials performed over time
Dianthus Therapeutics's quick ratio has surged by 101% YoY but it has decreased by 11% QoQ
The current ratio has soared by 99% YoY but it has contracted by 11% from the previous quarter
DNTH's debt is 100% smaller than its equity
DNTH's debt is down by 6% since the previous quarter and by 3.2% year-on-year
DNTH's equity is down by 2.4% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.